Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer
Background Immune checkpoint inhibitors (ICIs), including anti-PD-1 therapy, have limited efficacy in patients with microsatellite stable (MSS) colorectal cancer (CRC). Interleukin 17A (IL-17A) activity leads to a protumor microenvironment, dependent on its ability to induce the production of inflam...
Saved in:
Main Authors: | Chao Liu, Yang Yao, Jiaqi Shi, Ruiqi Liu, Bojun Wang, Jie Lian, Haoxiu Sun, Chunhui Zhang, Lin Fang, Xin Guan, Shuling Han, Fei Zhan, Shengnan Luo, Yuanfei Yao, Tongsen Zheng, Yanqiao Zhang |
---|---|
Format: | article |
Language: | EN |
Published: |
BMJ Publishing Group
2021
|
Subjects: | |
Online Access: | https://doaj.org/article/1543fccbb7ab42599845ba4d1df732b1 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Correction: Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer
Published: (2021) -
Mechanisms underlying low-clinical responses to PD-1/PD-L1 blocking antibodies in immunotherapy of cancer: a key role of exosomal PD-L1
by: Min Yu, et al.
Published: (2021) -
miR-15b-5p resensitizes colon cancer cells to 5-fluorouracil by promoting apoptosis via the NF-κB/XIAP axis
by: Ci Zhao, et al.
Published: (2017) -
Correction: Mechanisms underlying low-clinical responses to PD-1/PD-L1 blocking antibodies in immunotherapy of cancer: a key role of exosomal PD-L1
Published: (2021) -
Anti-Angiogenic Agent Combined with Anti-PD-1 Immunotherapy Showed Activity in Patients With Classical Hodgkin Lymphoma Who Have Failed Immunotherapy: A Retrospective Case Report Study
by: Zheng Yan, et al.
Published: (2021)